Clinical and quality of life assessment in patients with latex allergy during COVID-19 pandemic: Possible protective role of continuous latex immunotherapy. (14th May 2022)
- Record Type:
- Journal Article
- Title:
- Clinical and quality of life assessment in patients with latex allergy during COVID-19 pandemic: Possible protective role of continuous latex immunotherapy. (14th May 2022)
- Main Title:
- Clinical and quality of life assessment in patients with latex allergy during COVID-19 pandemic: Possible protective role of continuous latex immunotherapy
- Authors:
- Di Rienzo, Alessia
Urbani, Sara
Longhino, David
Sarnari, Caterina
Buonomo, Alessandro
Rizzi, Angela
Aruanno, Arianna
Nucera, Eleonora - Abstract:
- Introduction: During COVID-19 pandemic, the massive use of Personal Protective Equipment could provoke severe adverse reactions in latex allergy patients and could negatively affect their quality of life.Methods: Trough a survey the study aimed: (a) to evaluate the incidence of allergic reactions in patients with latex allergy during the SARS-CoV-2 pandemic; (b) to evaluate the protective role of continuous latex sublingual immunotherapy (SLIT) during this period; and (c) to evaluate quality of life of natural rubber latex allergy (NRLA) patients during the pandemic.Results: 67 patients (9 males and 58 females, mean age of 45.9 ± 11.4 years) suffering from latex allergy were included in the present study. We recorded among our patients 13 cases (34.2%) of urticarial/angioedema (U/A), 9 cases (23.6%) of respiratory symptoms (dyspnoea, shortness of breath and wheezing) and 7 cases (18.4%) of anaphylaxis. In patients who underwent continuous SLIT, we observed less cases of U/A ( p < 0.001), respiratory symptoms ( p < 0.001), anaphylaxis ( p = 0.003), hospitalizations ( p = 0.014) and a lower therapy administration. We compared the results of SF-36 questionnaire in patients who underwent continuous and not-continuous SLIT with a significance differences score between these two groups.Conclusions: Our study is the first that investigated the clinical and quality of life effects of COVID-19 pandemic in NRLA patients.
- Is Part Of:
- International journal of immunopathology and pharmacology. Volume 36(2022)
- Journal:
- International journal of immunopathology and pharmacology
- Issue:
- Volume 36(2022)
- Issue Display:
- Volume 36, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 36
- Issue:
- 2022
- Issue Sort Value:
- 2022-0036-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-05-14
- Subjects:
- Latex allergy -- immunotherapy -- COVID-19
Immunopathology -- Periodicals
Pharmacology -- Periodicals
Inflammation -- Periodicals
615.1 - Journal URLs:
- http://iji.sagepub.com/ ↗
http://www.uk.sagepub.com ↗ - DOI:
- 10.1177/03946320221100367 ↗
- Languages:
- English
- ISSNs:
- 0394-6320
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24259.xml